Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression Management.

In Model 3 (full model including both PS and BSC), the PS effect was completely attenuated and lost statistical significance (aHR 1.08, 95% CI 0.60–1.93, p = 0.802), while BSC remained highly significant (aHR 7.07, 95% CI 3.48–14.38, p < 0.0001).

also in 132,142 other papers

49.2%), although this difference did not reach statistical significance ( p = 0.053).

also in 111,027 other papers

Univariate Cox regression for OS (Table 3 ) revealed that poor baseline ECOG PS (2–3) was associated with worse survival (HR 1.72, 95% CI 1.02–2.92, p = 0.04), and major mutations showed a strong trend toward improved survival (HR 0.44, 95% CI 0.19–1.02, p = 0.055).

also in 5,725 other papers

Dose reduction showed a trend toward longer TTF (HR 0.66, 95% CI 0.40–1.10, p = 0.11), while age, sex, PS, and other AEs were not significantly associated with TTF.

also in 53,322 other papers